We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
216 (255 working days)
Active ingredients
baricitinib
Registration type
EOI
Indication
Atopic Dermatitis
OLUMIANT (tablet) is now also indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.